Fall Skin Care Sale

Scleroderma References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Mayes MD. The establishment and utility of a population-based registry to understand the epidemiology of systemic sclerosis. Curr Rheumatol Rep. 2000 Dec;2(6):512–6.
  2. Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am. 2003a May;29(2):239–54.
  3. Mayes MD, Lacey JV Jr, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003b Aug;48(8):2246–55.
  4. Cotran RS. Diseases of immunity. In: Cotran RS, Kumar V, Collins T, eds. Pathologic Basis of Disease. 6th ed. Philadelphia, Pa: W.B. Saunders; 1999:226–9.
  5. Clements PJ, Seibold JR, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: Lessons learned. Semin Arthritis Rheum. 2004 Feb;33(4):249–63.
  6. Furst DE. Rational therapy in the treatment of systemic sclerosis. Curr Opin Rheumatol. 2000 Nov;12(6):540–4.
  7. Furst DE, Clements PJ. D-penicillamine is not an effective treatment in systemic sclerosis. Scand J Rheumatol. 2001;30(4):189–91.
  8. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42(6):1194-203.
  9. Schiel WC. MedicineNet web page. Scleroderma. Available at: http://www.onhealth.com/scleroderma/page4.htm#what_is_the_treatment_for_scleroderma. 2013. Accessed 7/15/13.
  10. Zic JA, Miller JL, et al. The North American experience with photopheresis. Ther Apher. 1999 Feb;3(1):50–62.
  11. Krasagakis K, Dippel E, et al. Management of severe scleroderma with long-term extracorporeal photopheresis. Dermatology. 1998;196(3):309–15.
  12. Klyscz T, Rassner G, et al. Biomechanical stimulation therapy: A novel physiotherapy method for systemic sclerosis. Adv Exp Med Biol. 1999;455:309–16.
  13. Shiel Jr WC. Scleroderma. What is the treatment for scleroderma? Available at: http://www.medicinenet.com/scleroderma/page5.htm#what_is_the_treatment_for_scleroderma. October 29, 2012. Accessed October 29, 2012.
  14. Swanson BN. Medical use of dimethyl sulfoxide (DMSO).  Clin Basic Pharm. 1985 Jan-Jun;5(1-2):1-33.
  15. Williams HJ, Furst DE, et al. Double-blind, multicenter controlled trial comparing topical dimethyl 15sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis Rheum. 1985 Mar;28(3):308–14.
  16. Scherbel AL. The effect of percutaneous dimethyl sulfoxide on cutaneous manifestations of systemic sclerosis. Ann N Y Acad Sci. 1983;411:120–30.
  17. Horrobin DF. Essential fatty acid metabolism in diseases of connective tissue with special reference to scleroderma and to Sjogren’s syndrome. Med Hypotheses. 1984 Jul;14(3):233–47.
  18. Horrobin DF. Essential fatty acid and prostaglandin metabolism in Sjogren’s syndrome, systemic sclerosis and rheumatoid arthritis. Scand J Rheumatol Suppl. 1986;61:242–5.
  19. DiGiacomo RA, Kremer JM, et al. Fish-oil dietary supplementation in patients with Raynaud’s phenomenon: A double-blind, controlled, prospective study. Am J Med. 1989 Feb;86(2):158–64.
  20. Bruckdorfer KR, Hillary JB, et al. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum. 1995 Aug;38(8):1060–7.
  21. Herrick AL, Worthington H, et al. Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol. 1996 Apr;23(4):650–3.
  22. Sommerburg O, et al. Enhanced lipid peroxidation in systemic scleroderma. Z Dermatol. 1996;182(3):124, 126–8.
  23. Harada M, Kumemura H, et al. Scleroderma and repeated spontaneous abortions treated with vitamin E: A case report. Kurume Med J. 2005;52(3):93–5.
  24. Salsano F, Letizia C, et al. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon. Int J Immunopathol Pharmacol. 2005 Oct-Dec;18(4):761–70.
  25. Failli P, Palmieri L, et al. Effect of N-acetyl-L-cysteine on peroxynitrite and superoxide anion production of lung alveolar macrophages in systemic sclerosis. Nitric Oxide. 2002 Dec;7(4):277–82.
  26. Todisco M. Effectiveness of a treatment based on melatonin in five patients with systemic sclerosis. Am J Ther. 2006 Jan-Feb;13(1):84–7.
  27. Bonte F, Dumas M, et al. Influence of asiatic acid, madecassic acid, and asiaticoside on human collagen I synthesis. Planta Med. 1994 Apr;60(2):133–5.
  28. Maquart FX, Chastang F, et al. Triterpenes from Centella asiatica stimulate extracellular matrix accumulation in rat experimental wounds. Eur J Dermatol. 1999 Jun;9(4):289–96.
  29. Widgerow AD, Chait LA, et al. New innovations in scar management. Aesthetic Plast Surg. 2000 May;24(3):227–34.
  30. Guseva NG, Starovoitova MN, et al. [Madecassol treatment of systemic and localized scleroderma]. Ter Arkh. 1998;70(5):58–61.
  31. Vacca A, Cormier C, Mathieu A, et al. Vitamin D levels and potential impact in systemic sclerosis.Clin Exp Rheumatol. 2011 Nov-Dec;29(6):1024-31. Epub 2011 Dec 22.
  32. Caramaschi P, Dalla Gassa A, Ruzzenente O, et al. Very low levels of vitamin D in systemic sclerosis patients. Clin Rheumatol. 2010 Dec;29(12):1419-25. Epub 2010 May 9.